Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03169985 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Randomized Controlled Trial of Moderate-Intensity Rosuvastatin With Ezetimibe Combination Therapy Versus High-Intensity Rosuvastatin on Progression of Coronary Atherosclerotic Plaque

Study acronym: Rosuzet-IVUS
StatusActive, Not Recruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Recruiting to Active, Not Recruiting
    • Eligibility criteria expanded, about 94 words
    • Site details revised
    • Study title expanded, about 7 words
    v9
  2. Trial status: Active, Not Recruiting to Recruiting
    • Site details revised
    v8
  3. Primary completion date: Dec 31, 2023 to Jan 28, 2027
    • Trial status: Recruiting to Active, Not Recruiting
    • Study completion date: Dec 31, 2024 to Jan 28, 2027
    • Site details revised
    v7
  4. Primary completion date: Dec 31, 2022 to Dec 31, 2023v6
  5. Primary completion date: Dec 31, 2021 to Dec 31, 2022
    • Study completion date: Dec 31, 2023 to Dec 31, 2024
    v5
Show 3 earlier versionsHide 3 earlier versions
  1. Re-verified, no change to tracked fieldsv4
  2. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jun 1, 2017 to Jul 12, 2017
    • Site details revised
    v3
  3. Study description revisedv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The aim of this prospective, open-label, randomized, single center study is to compare the effect of usual dose rosuvastatin plus ezetimibe and high-dose rosuvastatin on modifying atherosclerotic plaque.
Trial Details
NCT Number NCT03169985
Lead Sponsor Samsung Medical Center
Collaborators: Hanmi Pharmaceutical co., ltd.
Conditions
(from sponsor)		 Coronary Artery Disease
Related terms Coronary Artery Disease, Plaque, Atherosclerotic
Enrollment 280 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov